Detalhe da pesquisa
1.
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite.
Br J Clin Pharmacol
; 90(2): 568-581, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37872122
2.
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.
Mol Cancer Ther
; 21(7): 1047-1059, 2022 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511740
3.
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
Cancer Chemother Pharmacol
; 79(2): 315-326, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28097385
4.
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.
Clin Cancer Res
; 23(17): 5015-5023, 2017 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28490463
5.
A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.
Mol Cancer Ther
; 14(11): 2463-72, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26304237
6.
Lymphoma and myeloma in older patients.
Semin Oncol
; 31(2): 198-205, 2004 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15112150